Overactive Bladder Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Astellas Pharma, Laborie, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ Overactive Bladder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Overactive Bladder Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.

The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Overactive Bladder Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.

*
Overactive Bladder companies working in the treatment market are Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others, are developing therapies for the Overactive Bladder treatment

*
Emerging Overactive Bladder therapies in the different phases of clinical trials are- ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.

*
In January 2025, Preliminary results from a Phase 1b trial (NCT06024642) indicate that Sunobinop (V117957), an oral therapy, showed early signs of efficacy and safety in treating patients with overactive bladder (OAB).

*
In April 2024, SpineX has completed patient enrollment for its CONTINENCE clinical trial (NCT05301335), which evaluates the Scone neuromodulation device for treating neurogenic bladder, often associated with conditions like multiple sclerosis (MS), stroke, or spinal cord injury. Conducted at multiple sites across the U.S., Canada, and India, the study targets adults experiencing overactive bladder symptoms due to these neurological conditions. Researchers at SpineX are optimistic that participants in the trial will experience notable enhancements in self-reported symptoms linked to neurogenic bladder.

*
In November 2023, Avation Medical has disclosed encouraging outcomes from the multi-center trial of Vivally, its medical device aimed at addressing overactive bladder (OAB) syndrome. The FREEOAB multi-center study involved 96 OAB patients. Findings indicated notable decreases in daily void, incontinence, and urgency episodes at the 12-week mark, leading to an improved quality of life. Furthermore, these favorable effects endured over the long term, with ongoing enhancements in diary parameters noted at the 12-month follow-up.

Overactive Bladder Overview

Overactive bladder (OAB) is a urinary condition characterized by a frequent and sudden urge to urinate that may be difficult to control. People with OAB often experience urinary urgency, which can lead to involuntary leakage of urine (urge incontinence). This condition can significantly impact daily life and quality of life.

Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight [https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:

*
ARD-380: Aardvark Therapeutics

*
URB937: Exxel Pharma

*
Botulax: Hugel

*
IMB-115: Imbrium Therapeutics

*
TAC-302: Taiho Pharmaceutical

*
URO-902: Sumitovant Biopharma

*
DA-8010: Dong-A ST

Overactive Bladder Route of Administration

Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Overactive Bladder Molecule Type

Overactive Bladder Products have been categorized under various Molecule types, such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Overactive Bladder Pipeline Therapeutics Assessment

*
Overactive Bladder Assessment by Product Type

*
Overactive Bladder By Stage and Product Type

*
Overactive Bladder Assessment by Route of Administration

*
Overactive Bladder By Stage and Route of Administration

*
Overactive Bladder Assessment by Molecule Type

*
Overactive Bladder by Stage and Molecule Type

DelveInsight's Overactive Bladder Report covers around 15+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Overactive Bladder Therapeutics Market include:

Key companies developing therapies for Overactive Bladder are - Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.

Overactive Bladder Pipeline Analysis:

The Overactive Bladder pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.

*
Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Overactive Bladder drugs and therapies [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Overactive Bladder Pipeline Market Drivers

*
Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.

Overactive Bladder Pipeline Market Barriers

*
However, lack of diagnosis and information about OAB, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.

Scope of Overactive Bladder Pipeline Drug Insight

*
Coverage: Global

*
Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others

*
Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others

*
Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies

*
Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers

Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Overactive Bladder Report Introduction

2. Overactive Bladder Executive Summary

3. Overactive Bladder Overview

4. Overactive Bladder- Analytical Perspective In-depth Commercial Assessment

5. Overactive Bladder Pipeline Therapeutics

6. Overactive Bladder Late Stage Products (Phase II/III)

7. Overactive Bladder Mid Stage Products (Phase II)

8. Overactive Bladder Early Stage Products (Phase I)

9. Overactive Bladder Preclinical Stage Products

10. Overactive Bladder Therapeutics Assessment

11. Overactive Bladder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Overactive Bladder Key Companies

14. Overactive Bladder Key Products

15. Overactive Bladder Unmet Needs

16 . Overactive Bladder Market Drivers and Barriers

17. Overactive Bladder Future Perspectives and Conclusion

18. Overactive Bladder Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=overactive-bladder-pipeline-2025-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-astellas-pharma-laborie-hisamitsu-pharma-inc-medtronic-pfizer-inc-teva-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.